Semaglutide Dosing and Administration

Dosing Titration Schedule

The triplicate equivalent to Ozempic (semaglutide) dosing follows a gradual titration schedule starting at 0.25 mg subcutaneously once weekly for 4 weeks, followed by incremental increases every 4 weeks (0.5 mg, 1.0 mg, 1.7 mg) until reaching the maintenance dose of 2.4 mg once weekly, as recommended by clinical guidelines 1
The dosing schedule is as follows: Week 1-4: 0.25 mg subcutaneously once weekly, Week 5-8: 0.5 mg subcutaneously once weekly, Week 9-12: 1.0 mg subcutaneously once weekly, Week 13-16: 1.7 mg subcutaneously once weekly, and Week 17 onwards: 2.4 mg subcutaneously once weekly (maintenance dose) 1

Gradual dose titration is essential to minimize gastrointestinal adverse effects, which are the most common side effects of semaglutide, according to Gastroenterology guidelines 2
If a patient misses 2 consecutive doses, clinical judgment is needed for subsequent dosing - consider resuming at the same dose if well-tolerated previously, or lowering the dose, as suggested by Gastroenterology 2
Some patients may achieve significant response at submaximal doses and could continue at that dose long-term, as noted in Gastroenterology 2

Semaglutide can be administered at any time of day, with or without meals, according to Praxis Medical Insights 1
If a dose is missed and it has been less than 5 days since the missed dose, administer as soon as possible; if more than 5 days have passed, skip the missed dose, as recommended by Praxis Medical Insights 1

Semaglutide should not be used with other GLP-1 receptor agonists or dipeptidyl peptidase-4 inhibitors, as stated in Gastroenterology 2
Use caution when combining with insulin or insulin secretagogues due to potential hypoglycemia risk; dose adjustments of these medications may be needed, according to Diabetes Care 3
No dosage adjustment is required for patients with renal impairment, as noted in Praxis Medical Insights 1

Semaglutide has shown greater weight loss efficacy compared to liraglutide (8.0% weight loss at 56 weeks for liraglutide vs. 9.6% for semaglutide 2.4 mg), as reported in Diabetes Care and JAMA 4, 5
Tirzepatide has demonstrated greater weight loss compared to semaglutide in recent studies (mean difference of 5.1% greater weight loss with 15 mg tirzepatide compared to 2.4 mg semaglutide), according to JAMA 5

Semaglutide has demonstrated cardiovascular benefits in patients with type 2 diabetes and in those with obesity without diabetes, as reported in JAMA 5
The SELECT study showed that in participants with cardiovascular disease and BMI ≥27 without diabetes, semaglutide 2.4 mg reduced the composite incidence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke (hazard ratio, 0.80), as published in JAMA 5